Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman

Core Viewpoint - Tiziana Life Sciences is advancing its lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, which has shown promising results in treating neuroinflammatory and neurodegenerative diseases, particularly in patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) [1][2][3]. Group 1: Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies using transformational drug delivery technologies [4]. - The company’s lead candidate, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody currently in clinical development, demonstrating a favorable safety profile and clinical response in previous studies [4]. - Tiziana's intranasal approach aims to improve efficacy, safety, and tolerability compared to traditional intravenous delivery methods [4]. Group 2: Product Development - Foralumab has been administered to 14 patients with na-SPMS in an open-label Expanded Access Program, with all patients showing either improvement or stability of disease within six months [2]. - The drug is also undergoing a Phase 2a randomized, double-blind, placebo-controlled trial to further assess its efficacy in patients with non-active secondary progressive multiple sclerosis [2][3]. - The immunomodulation potential of intranasal foralumab represents a novel treatment avenue for neuroinflammatory and neurodegenerative diseases [3]. Group 3: Executive Actions - Mr. Gabriele Cerrone, the Executive Chairman and Founder of Tiziana, has purchased 97,687 common shares, increasing his total holdings to 43,374,830 shares, which constitutes 36.08% of the company's issued share capital [1].